Stock Report

All about this stock under one free report Last Updated: 06-Sep-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

This month’s issue could change how you invest, read now.

Recently Viewed

Clear All

Arcutis Biotherapeutics Inc (ARQT) Peer Comparison

Stock Card factsheet share-fund-plan-icon

$23.90

up-down-arrow $0.24 (1.01%)

As on 04-Sep-2026 16:00EDT

Market cap

info icon

$2,989 Mln

Revenue (TTM)

info icon

$464 Mln

P/E Ratio

info icon

108.1

P/B Ratio

info icon

14.2

Div. Yield

info icon

0 %

Edit peer-selector-edit
Arcutis Biotherapeutics Inc (ARQT) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Madrigal Pharmaceuticals (MDGL)
Market cap ($ Mln)
 2,989 16,765 16,261 13,492 12,332
Revenue ($ Mln)
 464 2,782 1,054 2,436 1,284
Net Profit ($ Mln)
 28.52 491.50 755.85 860.62 -325.10
Net Margin (%)
 6.15 17.67 71.69 35.33 -25.32
RoE (%)
 13.91 110.09 -- 42.98 -57.72
Price to Earnings
 108.09 35.25 19.00 17.40 --
Price-To-Book
 14.16 39.29 9.76 7.42 23.98

Income Statement ($ Mln)

Arcutis Biotherapeutics Inc (ARQT) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Madrigal Pharmaceuticals (MDGL)
Operating Revenue arrow
463.98 2,782.29 1,054.37 2,435.92 1,283.94
Cost of Revenue arrow
41.10 1,982.07 103.47 85.67 109.42
Gross Profit arrow
339.38 760.62 588.53 2,236.43 902.26
Operating Expenses arrow
388.63 216.81 841.45 1,378.74 1,497.13
Operating Profit (EBIT) arrow
34.25 583.40 109.45 971.51 -322.62
Other Income arrow
0.00 0.00 0.00 0.00 0.00
Profit before Tax arrow
29.30 598.92 101.11 1,035.47 -325.10
Provision for Tax arrow
0.78 107.42 -654.74 174.84 0.00
Profit after Tax (Net Income) arrow
28.52 491.50 755.85 860.62 -325.10
Minority Interest arrow
0.00 0.00 0.00 0.00 0.00
Consolidated Profit arrow
0.00 0.00 0.00 0.00 0.00

Liabilities ($ Mln)

Arcutis Biotherapeutics Inc (ARQT) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Madrigal Pharmaceuticals (MDGL)
Shareholder's Funds arrow
220.58 433.86 1,435.90 1,843.76 523.72
Minority Interest arrow
0.00 0.00 0.00 0.00 0.00
Non-Current Liabilities arrow
107.62 187.89 384.48 288.55 346.72
Current Liabilities arrow
160.34 1,435.43 464.70 361.93 374.20
Total Liabilities arrow
432.97 1,975.47 1,302.02 2,844.42 1,259.59

Assets ($ Mln)

Arcutis Biotherapeutics Inc (ARQT) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Madrigal Pharmaceuticals (MDGL)
Non-Current Assets arrow
20.87 1,006.90 895.24 1,243.41 45.47
Current Assets arrow
467.67 1,050.29 1,389.84 1,250.82 1,199.18
Total Assets arrow
432.97 1,975.47 1,302.02 2,844.42 1,259.59
Total Debt* arrow
114.14 120.10 449.89 165.93 347.75
Net Current Assets arrow
307.33 -385.14 0.00 888.90 824.98

Cashflow ($ Mln)

Arcutis Biotherapeutics Inc (ARQT) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Madrigal Pharmaceuticals (MDGL)
Cash From Operating Activities arrow
-5.63 713.22 51.77 884.27 -189.55
Cash Flow from Investing Activities arrow
-30.25 -31.14 -8.15 350.44 32.32
Cash from Financing Activities arrow
6.97 -860.39 34.89 -969.59 255.98
Net Cash Inflow / Outflow arrow
-- -- -- -- --

Ratios

Profitability Ratios

 Arcutis Biotherapeutics Inc (ARQT) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Madrigal Pharmaceuticals (MDGL)
ROCE (%) arrow
-6.96 53.56 -30.01 32.82 -31.49
ROE (%) arrow
13.91 110.09 163.18 42.98 -57.72
ROA (%) arrow
5.16 15.64 26.53 29.32 -22.97
EBIT Margin (%) arrow
8.88 21.13 5.73 31.04 -18.97
Net Margin (%) arrow
6.15 17.67 71.69 35.33 -25.32
Cash Profit Margin (%) arrow
0.00 0.00 0.00 0.00 0.00

Growth Ratios

 Arcutis Biotherapeutics Inc (ARQT) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Madrigal Pharmaceuticals (MDGL)
Revenue Growth (%) arrow
76.11 24.67 114.85 9.23 149.04
EBIT Growth (%) arrow
155.56 18.70 136.39 -3.99 9.16
Net Profit Growth (%) arrow
130.58 17.50 378.76 42.89 -15.32
EPS Growth (%) arrow
127.72 26.84 353.27 50.42 -0.64
Book Value Growth (%) arrow
48.32 164.02 816.12 -0.70 -42.66

Valuation Ratios

 Arcutis Biotherapeutics Inc (ARQT) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Madrigal Pharmaceuticals (MDGL)
Price / Earnings arrow
-244.03 36.06 -59.76 15.79 -45.32
Price / Book Value arrow
20.79 35.44 -80.42 5.72 21.68
Dividend Yield (%) arrow
-- -- -- -- --
EV/EBITDA arrow
1,501.66 28.08 -121.54 12.44 -47.02
Market Cap ($ Cr) arrow
-- -- -- -- --

Solvency Ratios

 Arcutis Biotherapeutics Inc (ARQT) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Madrigal Pharmaceuticals (MDGL)
Debt to Equity arrow
0.46 0.00 0.00 0.00 0.65
Short term debt to equity ratio arrow
0.03 0.00 0.05 0.00 0.00
Current Ratio arrow
2.92 0.73 2.99 3.46 3.20
Quick Ratio arrow
2.67 0.73 2.32 3.38 2.94
Interest Coverage arrow
3.12 -- 1.62 -- -19.80

Operating Efficiency Ratios

 Arcutis Biotherapeutics Inc (ARQT) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Madrigal Pharmaceuticals (MDGL)
Debtors to sales (%) arrow
33.44 15.88 21.25 13.74 14.98
Asset Turnover arrow
0.84 0.89 0.37 0.83 0.91
Receivable days arrow
106.49 50.42 85.52 43.48 35.88
Inventory Days arrow
184.94 -- 1,056.70 96.17 354.23
Payable days arrow
133.12 6.26 331.01 147.97 300.79
Cash Conversion Cycle arrow
158.31 -- 811.21 -8.32 89.33
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...